Outcomes of 219 chronic myeloid leukaemia patients with additional chromosomal abnormalities and/or tyrosine kinase domain mutations

Abstract

Introduction To confirm the role of additional chromosomal abnormalities (ACAs) and kinase domain (KD) mutations in the progression and outcomes of Chronic myeloid leukaemia (CML) patients and the connection between them, we analysed the ACAs and KD mutations of 219 CML patients admitted to our hospital. Methods Cytogenetic analysis of metaphases was performed to detect ACAs, and the BCR‐ABL1 KD was sequenced to detect KD mutations. Results Twenty‐four patients (11.0%) had ACAs in addition to the BCR‐ABL1 or t(9;22)(q34;q11) translocation. The most common abnormality was trisomy 8. Twelve different KD mutations were observed in 13 out of 53 imatinib‐resistant patients (24.5%). p.(Y235H) (n = 3; 23.07%), p.(F359V) and p.(T315I) (n = 2; 15.38%) presented most frequently. KD mutations subtypes (p.(E255K), p.(T315I), p.(F359V), p.(M244V) and p.(L298V)) coexisted with ACAs. The incidence of CML progression was 12/22 (54.5%) in the group of patients with ACAs and/or KD mutations and 2/143 (1.4%) in the group of patients without ACAs or KD mutations (CI 95%, P < 0.001) and was higher in the KD mutations group than in the ACAs group (P = 0.046). The group of patients with ACAs and/or KD mutations had more men than the group of patients without ACAs or KD mutations (P = 0.013). Conclusion We conclude that ACAs and/or KD mutations are related to CML progression and are adverse outcome factors. Their presence exhibits gender differences and is more common in males. p.(E255K), p.(T315I), p.(F359V), p.(M244V) and p.(L298V) emerge more frequently when ACAs and KD mutations coexist.

Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids

“…Multidrug resistance (MDR) is one of the major challenges in cancer treatment (1), which occurs in a short period of time during/after treatment, and may result in cross resistance to many other structurally and mechanically different chemotherapeutics (2). MDR may be due to different mechanisms, including (1) ATP-binding cassette (ABC) transporters that pump out chemotherapeutics (3), (2) the mutation of oncogenes that become resistant to former treatments (4, 5), (3) an evolving adaptation of cancer cells to the microenvironment (6, 7), (4) survived cancer stem cells (CSCs) that escape from conventional therapies (8, 9), and (5) activated cell growth factors as well as cell defense systems, etc.…”

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells

“…Multidrug resistance (MDR) is one of the main reasons leading to failure of chemotherapy in cancers ( 1 , 2 ). Several mechanisms of MDR have been elucidated, including the increase of intracellular drug efflux ( 3 ), cell apoptosis inhibition ( 4 ), DNA repair enhancement ( 5 ) oncogene mutations ( 6 ) and others. Among them, ATP-binding cassette (ABC) transporters-mediated drug resistance is one of the most important factor causing MDR in cancer ( 7 ).…”

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

“…Detection of a mutation identifies patients at greater risk of subsequent relapse [6]. In the past, mutations (especially the T315I and the P-loop mutations G250E, Q252H, Y253H/F, E255K/V) had also been associated with significantly shorter progression-free and overall survival [7–13]. In more recent times, a negative prognostic impact has not been observed in all studies [14], suggesting that the expanded drug armamentarium and the wider and wider use of mutation testing in routine practice have been beneficial.…”